and and for our joining us to Zdravka. Thank be you today. earnings the my with thank I'm Alan call you, colleagues, our all on Tom Alan, on call -- happy
During in achievements we and and made have I'm considerable proud has our XXXX, continuing into made progress. XXXX. very the of team XXXX efforts
candidate. clinic genetic using to of interest or forward metastasis multiple using as lead our requires move system therapeutic are to with enter continue on There targets approaches, RNA. fronts many and repair Targeting using RNAi, tumor as Pattern types. the including messenger in on gene We the prepare CRISPR linked solid dozens we to and well replacement genes different these or Recognition vaccines turning cancer immune RNA as Receptors of interference cancer
extensively And lab then the driver XX our to over validated has by deliver four safely to expect therapeutics sets tumor optimized metastases. in oncology lead generic clinical an inside the it RNA others. peer achieve cancer therapeutic tumor in will molecule, and first-in-human own because that's We been targets has changing the system proprietary are and effectiveness that to RNA shown we us it in targets different been developing these across a we treatment. we cancer. our developed and results XXX treat we breakthrough apart should potential As have we've trial, that If game is the that a of believe We RNA candidates each tremendous RNA distinct represent believe that disease be of approaches reviewed metastatic in of what therapeutic to enable company, already candidate our approaches types. believe publications our been cells
we As later eIND our this our to year. first-in-human take to indicated our place recent intend clinical in filing, study for file
portfolio, what our patients TTX therapeutics power mechanism potential efficient. are process, expect can team, extensive provide take of proof experienced study, call on we expose And delivery will group. have the potentially the our we millions in demonstrated time. help steps the to next our management first-in-human platform, success have the and powerful RNA trial platform. advisory and Directors that we of after oncology Board that of We this very first an we of capital the Besides world. And around We for science for highly we we believe demonstrate IP in that a
six from considerably grown has we that to advancing. and platform two a asset assets single therapeutic therapeutic Our are diagnostic assays
I lead this schedule year. our the to candidate mentioned, clinic is on enter therapeutic As TTX-MCXXX
other of RNA approaches. therapeutic of stages about candidates to And various development preclinical excited discovery were variety cancer of from we're these treat Our in assessment. candidates using to all a
organ And metastatic And nearly an leave and And basis. need, current XX% year, on last COVID-XX unmet enormous for other though tumor parts Metastasis travel this Just tumors treatments cancer even but date. cells, ours does. to of the died target cells annual not XX tumor from around disease of cancer than there's in tumor primary -- metastatic an do million the origin to specifically world cancer, of nearly the body. those happens more when deaths. people occurs accounts
responsible molecule and types. tumor RNA microRNA-XXb, Our has metastatic known these for in which migration, of an survival been proven multiple targets cell lead candidate tumor cells therapeutic invasion as
its expressed with microRNA-XXb studies no metastases TTX-MCXXX target since and the resulting potential in preclinical established TTX-MCXXX XX show that of has is types. targets broad across tumor therapeutic Our regression toxicity. no different recurrence inhibited it --
clinical potential that the we've be in results drug, the to results achieved achieve a animals. significant we should mirror has it So,
code. molecules our RNA drug known synthetic to can nature rapidly expanding with correspond of the different this in cancer gives the advantage oligo knowledge, especially this for an knowledge cancer. advantage that toolbox, Our of our of about approach convert component means advantage We believe as module determine this And interest. over of target, responsible distinct delivery code system. of us that's of we the to really our development synthesize the or genome, can TransCode harmonized are we to genes about human is key what the we takes genome take the what what that oligonucleotides, targets that's knowledge others that Armed the generic target. to design to coded Once generic
the of of metastases Our a proprietary specifications been relevant tumor liver put oligos to simply, to -- RNAs to Yet responsible can significant for modified using in approach. outside decades. the targeting undruggable therapeutic the RNA the lack without in oligonucleotides Clinically direct pursued tumors the which tumor currently has major pre-designed being To metastasis generic or Literature most molecules, target, cells. an it which delivery delivery are on there's within and cell. body. targets of system throughout a monoclonal initiation antibodies remained these be are delivery for of bounds to tumor however for of cells cancer of lies challenge of success and general small
nanoparticle leverages successfully known to imaging been as that's strategy sites. used in an decades for also agent metastatic unique Our accumulate that is
And nanoparticle we're potential. known success RNA our We excited is so therapeutics. deliver delivery to about have why repurposed this this
of other therapeutic Aside treatment tumor solid two of treatment types. a also candidates variety potential for in from TTX-MCXXX metastasis, of our broad have of
is first to PD-LX. RNAi The approach an
including to body that Our cancer. help fight the diseases, immune and designed other system utilizes T-cells, infections cells are
However, protein to PD-LX. a Keytruda, inhibitors Yervoy stop works PD-LX cancer block inactivate can expression. work to Checkpoint and expressing cells called Tecentriq a T-cells. by PD-LX like T-cells and like escape and others sign PD-X
believe PD-LX and synthesis quite the approach which more function. of We tumor We earlier death. at is our potential to the efficient, altogether tumors level the different. to cell prevent in However, to approach could attempt our lead result of has recognition rather than block its T-cell be cellular
we We targeting is also that mechanism. are the believe using RNAi an PD-LX company only
encouraging, We we results studies this cancer therapeutic models have so are this recently data and this The expect started later preclinical far very candidate pancreatic publish in to for year. and animals.
third those are activated Recognition recognized retinoic our in lead an immune called Receptor system. as the pathway. TTX-RIGA or response to we RIG-I a to RIG-I RNA cancer foreign. has immune A induced recognizes distinct against Once once have been Tumor work go eradicate types. rejection is immune body's theorized also the reported of that rejecting gene, viruses. RIG-I, activation is been Our RIG-I tumors it develop signature that is innate already animal like candidate therapeutic can studies it via engagement advancing viruses system targeting Pattern can cancer. gene immunity, by a structures multiple to into inducible would acid the and has cancer RIG-I that
cancer designed target, new candidate evaluate we to employ Once we believe development our capital against design save delivery new By and to then go create generic which we candidate preclinical that cells resources can response therapeutic combining therapies. and against therapeutic tumor elicit immune to target determine our one proprietary Our and inside optimized to and therapeutic after one next activate with RIG-I to time valuable therapeutic system toolbox new intended engine, generic as those design cancer target. we cells. an our targets and specific is is can
In design which fact, we there against therapeutics. are dozens could associated targets of relevant with generic cancer
libraries have to targets if the approach optimize RNA depending we against on potential develop therapeutic the So, agents molecular selected.
our our shed light to walks very as in more as Tom? results. To the CFO, provide will our he Tom, CFO, financial on allows manner importantly, will a us Fitzgerald, Tom More an full effective cause conduct of overview through that, indicate development you financials. year
